Global PARP Inhibitors for Cancer Market Research Report 2023
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
According to QYResearch’s new survey, global PARP Inhibitors for Cancer market is projected to reach US$ 13040 million in 2029, increasing from US$ 5904.1 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PARP Inhibitors for Cancer market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PARP Inhibitors for Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global PARP Inhibitors for Cancer market is projected to reach US$ 13040 million in 2029, increasing from US$ 5904.1 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PARP Inhibitors for Cancer market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PARP Inhibitors for Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- AstraZeneca
- Tesaro
- Merck & Co
- Clovis Oncology
- Pfizer
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
- Ovarian Cancer
- Breast Cancer
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 PARP INHIBITORS FOR CANCER MARKET OVERVIEW
1.1 Product Overview and Scope of PARP Inhibitors for Cancer
1.2 PARP Inhibitors for Cancer Segment by Type
1.2.1 Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 PARP Inhibitors for Cancer Segment by Application
1.3.1 Global PARP Inhibitors for Cancer Market Value by Application: (2023-2029)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP Inhibitors for Cancer Market Size Estimates and Forecasts
1.4.1 Global PARP Inhibitors for Cancer Revenue 2018-2029
1.4.2 Global PARP Inhibitors for Cancer Sales 2018-2029
1.4.3 Global PARP Inhibitors for Cancer Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PARP INHIBITORS FOR CANCER MARKET COMPETITION BY MANUFACTURERS
2.1 Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers (2018-2023)
2.2 Global PARP Inhibitors for Cancer Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PARP Inhibitors for Cancer Average Price by Manufacturers (2018-2023)
2.4 Global PARP Inhibitors for Cancer Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PARP Inhibitors for Cancer, Product Type & Application
2.7 PARP Inhibitors for Cancer Market Competitive Situation and Trends
2.7.1 PARP Inhibitors for Cancer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PARP Inhibitors for Cancer Players Market Share by Revenue
2.7.3 Global PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PARP INHIBITORS FOR CANCER RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global PARP Inhibitors for Cancer Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PARP Inhibitors for Cancer Global PARP Inhibitors for Cancer Sales by Region: 2018-2029
3.2.1 Global PARP Inhibitors for Cancer Sales by Region: 2018-2023
3.2.2 Global PARP Inhibitors for Cancer Sales by Region: 2024-2029
3.3 Global PARP Inhibitors for Cancer Global PARP Inhibitors for Cancer Revenue by Region: 2018-2029
3.3.1 Global PARP Inhibitors for Cancer Revenue by Region: 2018-2023
3.3.2 Global PARP Inhibitors for Cancer Revenue by Region: 2024-2029
3.4 North America PARP Inhibitors for Cancer Market Facts & Figures by Country
3.4.1 North America PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.4.3 North America PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PARP Inhibitors for Cancer Market Facts & Figures by Country
3.5.1 Europe PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.5.3 Europe PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PARP Inhibitors for Cancer Market Facts & Figures by Country
3.6.1 Asia Pacific PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.6.3 Asia Pacific PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America PARP Inhibitors for Cancer Market Facts & Figures by Country
3.7.1 Latin America PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.7.3 Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PARP Inhibitors for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.8.3 Middle East and Africa PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global PARP Inhibitors for Cancer Sales by Type (2018-2029)
4.1.1 Global PARP Inhibitors for Cancer Sales by Type (2018-2023)
4.1.2 Global PARP Inhibitors for Cancer Sales by Type (2024-2029)
4.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
4.2 Global PARP Inhibitors for Cancer Revenue by Type (2018-2029)
4.2.1 Global PARP Inhibitors for Cancer Revenue by Type (2018-2023)
4.2.2 Global PARP Inhibitors for Cancer Revenue by Type (2024-2029)
4.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
4.3 Global PARP Inhibitors for Cancer Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global PARP Inhibitors for Cancer Sales by Application (2018-2029)
5.1.1 Global PARP Inhibitors for Cancer Sales by Application (2018-2023)
5.1.2 Global PARP Inhibitors for Cancer Sales by Application (2024-2029)
5.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
5.2 Global PARP Inhibitors for Cancer Revenue by Application (2018-2029)
5.2.1 Global PARP Inhibitors for Cancer Revenue by Application (2018-2023)
5.2.2 Global PARP Inhibitors for Cancer Revenue by Application (2024-2029)
5.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
5.3 Global PARP Inhibitors for Cancer Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AstraZeneca PARP Inhibitors for Cancer Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Tesaro
6.2.1 Tesaro Corporation Information
6.2.2 Tesaro Description and Business Overview
6.2.3 Tesaro PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Tesaro PARP Inhibitors for Cancer Product Portfolio
6.2.5 Tesaro Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Corporation Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck & Co PARP Inhibitors for Cancer Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 Clovis Oncology
6.4.1 Clovis Oncology Corporation Information
6.4.2 Clovis Oncology Description and Business Overview
6.4.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Clovis Oncology PARP Inhibitors for Cancer Product Portfolio
6.4.5 Clovis Oncology Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer PARP Inhibitors for Cancer Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 PARP Inhibitors for Cancer Industry Chain Analysis
7.2 PARP Inhibitors for Cancer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PARP Inhibitors for Cancer Production Mode & Process
7.4 PARP Inhibitors for Cancer Sales and Marketing
7.4.1 PARP Inhibitors for Cancer Sales Channels
7.4.2 PARP Inhibitors for Cancer Distributors
7.5 PARP Inhibitors for Cancer Customers
8 PARP INHIBITORS FOR CANCER MARKET DYNAMICS
8.1 PARP Inhibitors for Cancer Industry Trends
8.2 PARP Inhibitors for Cancer Market Drivers
8.3 PARP Inhibitors for Cancer Market Challenges
8.4 PARP Inhibitors for Cancer Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of PARP Inhibitors for Cancer
1.2 PARP Inhibitors for Cancer Segment by Type
1.2.1 Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 PARP Inhibitors for Cancer Segment by Application
1.3.1 Global PARP Inhibitors for Cancer Market Value by Application: (2023-2029)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP Inhibitors for Cancer Market Size Estimates and Forecasts
1.4.1 Global PARP Inhibitors for Cancer Revenue 2018-2029
1.4.2 Global PARP Inhibitors for Cancer Sales 2018-2029
1.4.3 Global PARP Inhibitors for Cancer Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PARP INHIBITORS FOR CANCER MARKET COMPETITION BY MANUFACTURERS
2.1 Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers (2018-2023)
2.2 Global PARP Inhibitors for Cancer Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PARP Inhibitors for Cancer Average Price by Manufacturers (2018-2023)
2.4 Global PARP Inhibitors for Cancer Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PARP Inhibitors for Cancer, Product Type & Application
2.7 PARP Inhibitors for Cancer Market Competitive Situation and Trends
2.7.1 PARP Inhibitors for Cancer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PARP Inhibitors for Cancer Players Market Share by Revenue
2.7.3 Global PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PARP INHIBITORS FOR CANCER RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global PARP Inhibitors for Cancer Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PARP Inhibitors for Cancer Global PARP Inhibitors for Cancer Sales by Region: 2018-2029
3.2.1 Global PARP Inhibitors for Cancer Sales by Region: 2018-2023
3.2.2 Global PARP Inhibitors for Cancer Sales by Region: 2024-2029
3.3 Global PARP Inhibitors for Cancer Global PARP Inhibitors for Cancer Revenue by Region: 2018-2029
3.3.1 Global PARP Inhibitors for Cancer Revenue by Region: 2018-2023
3.3.2 Global PARP Inhibitors for Cancer Revenue by Region: 2024-2029
3.4 North America PARP Inhibitors for Cancer Market Facts & Figures by Country
3.4.1 North America PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.4.3 North America PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PARP Inhibitors for Cancer Market Facts & Figures by Country
3.5.1 Europe PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.5.3 Europe PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PARP Inhibitors for Cancer Market Facts & Figures by Country
3.6.1 Asia Pacific PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.6.3 Asia Pacific PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America PARP Inhibitors for Cancer Market Facts & Figures by Country
3.7.1 Latin America PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.7.3 Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PARP Inhibitors for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa PARP Inhibitors for Cancer Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2018-2029)
3.8.3 Middle East and Africa PARP Inhibitors for Cancer Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global PARP Inhibitors for Cancer Sales by Type (2018-2029)
4.1.1 Global PARP Inhibitors for Cancer Sales by Type (2018-2023)
4.1.2 Global PARP Inhibitors for Cancer Sales by Type (2024-2029)
4.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
4.2 Global PARP Inhibitors for Cancer Revenue by Type (2018-2029)
4.2.1 Global PARP Inhibitors for Cancer Revenue by Type (2018-2023)
4.2.2 Global PARP Inhibitors for Cancer Revenue by Type (2024-2029)
4.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
4.3 Global PARP Inhibitors for Cancer Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global PARP Inhibitors for Cancer Sales by Application (2018-2029)
5.1.1 Global PARP Inhibitors for Cancer Sales by Application (2018-2023)
5.1.2 Global PARP Inhibitors for Cancer Sales by Application (2024-2029)
5.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
5.2 Global PARP Inhibitors for Cancer Revenue by Application (2018-2029)
5.2.1 Global PARP Inhibitors for Cancer Revenue by Application (2018-2023)
5.2.2 Global PARP Inhibitors for Cancer Revenue by Application (2024-2029)
5.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
5.3 Global PARP Inhibitors for Cancer Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AstraZeneca PARP Inhibitors for Cancer Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Tesaro
6.2.1 Tesaro Corporation Information
6.2.2 Tesaro Description and Business Overview
6.2.3 Tesaro PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Tesaro PARP Inhibitors for Cancer Product Portfolio
6.2.5 Tesaro Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Corporation Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck & Co PARP Inhibitors for Cancer Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 Clovis Oncology
6.4.1 Clovis Oncology Corporation Information
6.4.2 Clovis Oncology Description and Business Overview
6.4.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Clovis Oncology PARP Inhibitors for Cancer Product Portfolio
6.4.5 Clovis Oncology Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer PARP Inhibitors for Cancer Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 PARP Inhibitors for Cancer Industry Chain Analysis
7.2 PARP Inhibitors for Cancer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PARP Inhibitors for Cancer Production Mode & Process
7.4 PARP Inhibitors for Cancer Sales and Marketing
7.4.1 PARP Inhibitors for Cancer Sales Channels
7.4.2 PARP Inhibitors for Cancer Distributors
7.5 PARP Inhibitors for Cancer Customers
8 PARP INHIBITORS FOR CANCER MARKET DYNAMICS
8.1 PARP Inhibitors for Cancer Industry Trends
8.2 PARP Inhibitors for Cancer Market Drivers
8.3 PARP Inhibitors for Cancer Market Challenges
8.4 PARP Inhibitors for Cancer Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global PARP Inhibitors for Cancer Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global PARP Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2022
Table 4. Global PARP Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers (2018-2023)
Table 6. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global PARP Inhibitors for Cancer Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market PARP Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of PARP Inhibitors for Cancer, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PARP Inhibitors for Cancer, Product Type & Application
Table 12. Global Key Manufacturers of PARP Inhibitors for Cancer, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PARP Inhibitors for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Cancer as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PARP Inhibitors for Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global PARP Inhibitors for Cancer Sales by Region (2018-2023) & (K Units)
Table 18. Global PARP Inhibitors for Cancer Sales Market Share by Region (2018-2023)
Table 19. Global PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 20. Global PARP Inhibitors for Cancer Sales Market Share by Region (2024-2029)
Table 21. Global PARP Inhibitors for Cancer Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2023)
Table 23. Global PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2024-2029)
Table 25. North America PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 27. North America PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 28. North America PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 32. Europe PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 33. Europe PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific PARP Inhibitors for Cancer Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific PARP Inhibitors for Cancer Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific PARP Inhibitors for Cancer Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 42. Latin America PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 43. Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global PARP Inhibitors for Cancer Sales (K Units) by Type (2018-2023)
Table 51. Global PARP Inhibitors for Cancer Sales (K Units) by Type (2024-2029)
Table 52. Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2023)
Table 53. Global PARP Inhibitors for Cancer Sales Market Share by Type (2024-2029)
Table 54. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Type (2018-2023)
Table 55. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Type (2024-2029)
Table 56. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2023)
Table 57. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2024-2029)
Table 58. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2018-2023)
Table 59. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2024-2029)
Table 60. Global PARP Inhibitors for Cancer Sales (K Units) by Application (2018-2023)
Table 61. Global PARP Inhibitors for Cancer Sales (K Units) by Application (2024-2029)
Table 62. Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2023)
Table 63. Global PARP Inhibitors for Cancer Sales Market Share by Application (2024-2029)
Table 64. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Application (2018-2023)
Table 65. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Application (2024-2029)
Table 66. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2023)
Table 67. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2024-2029)
Table 68. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2018-2023)
Table 69. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2024-2029)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. AstraZeneca PARP Inhibitors for Cancer Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Tesaro Corporation Information
Table 76. Tesaro Description and Business Overview
Table 77. Tesaro PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Tesaro PARP Inhibitors for Cancer Product
Table 79. Tesaro Recent Developments/Updates
Table 80. Merck & Co Corporation Information
Table 81. Merck & Co Description and Business Overview
Table 82. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck & Co PARP Inhibitors for Cancer Product
Table 84. Merck & Co Recent Developments/Updates
Table 85. Clovis Oncology Corporation Information
Table 86. Clovis Oncology Description and Business Overview
Table 87. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Clovis Oncology PARP Inhibitors for Cancer Product
Table 89. Clovis Oncology Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Pfizer PARP Inhibitors for Cancer Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. PARP Inhibitors for Cancer Distributors List
Table 98. PARP Inhibitors for Cancer Customers List
Table 99. PARP Inhibitors for Cancer Market Trends
Table 100. PARP Inhibitors for Cancer Market Drivers
Table 101. PARP Inhibitors for Cancer Market Challenges
Table 102. PARP Inhibitors for Cancer Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 1. Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global PARP Inhibitors for Cancer Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global PARP Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2022
Table 4. Global PARP Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers (2018-2023)
Table 6. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global PARP Inhibitors for Cancer Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market PARP Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of PARP Inhibitors for Cancer, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PARP Inhibitors for Cancer, Product Type & Application
Table 12. Global Key Manufacturers of PARP Inhibitors for Cancer, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PARP Inhibitors for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Cancer as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PARP Inhibitors for Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global PARP Inhibitors for Cancer Sales by Region (2018-2023) & (K Units)
Table 18. Global PARP Inhibitors for Cancer Sales Market Share by Region (2018-2023)
Table 19. Global PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 20. Global PARP Inhibitors for Cancer Sales Market Share by Region (2024-2029)
Table 21. Global PARP Inhibitors for Cancer Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2023)
Table 23. Global PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2024-2029)
Table 25. North America PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 27. North America PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 28. North America PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 32. Europe PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 33. Europe PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific PARP Inhibitors for Cancer Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific PARP Inhibitors for Cancer Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific PARP Inhibitors for Cancer Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 42. Latin America PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 43. Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global PARP Inhibitors for Cancer Sales (K Units) by Type (2018-2023)
Table 51. Global PARP Inhibitors for Cancer Sales (K Units) by Type (2024-2029)
Table 52. Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2023)
Table 53. Global PARP Inhibitors for Cancer Sales Market Share by Type (2024-2029)
Table 54. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Type (2018-2023)
Table 55. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Type (2024-2029)
Table 56. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2023)
Table 57. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2024-2029)
Table 58. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2018-2023)
Table 59. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2024-2029)
Table 60. Global PARP Inhibitors for Cancer Sales (K Units) by Application (2018-2023)
Table 61. Global PARP Inhibitors for Cancer Sales (K Units) by Application (2024-2029)
Table 62. Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2023)
Table 63. Global PARP Inhibitors for Cancer Sales Market Share by Application (2024-2029)
Table 64. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Application (2018-2023)
Table 65. Global PARP Inhibitors for Cancer Revenue (US$ Million) by Application (2024-2029)
Table 66. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2023)
Table 67. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2024-2029)
Table 68. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2018-2023)
Table 69. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2024-2029)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. AstraZeneca PARP Inhibitors for Cancer Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Tesaro Corporation Information
Table 76. Tesaro Description and Business Overview
Table 77. Tesaro PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Tesaro PARP Inhibitors for Cancer Product
Table 79. Tesaro Recent Developments/Updates
Table 80. Merck & Co Corporation Information
Table 81. Merck & Co Description and Business Overview
Table 82. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck & Co PARP Inhibitors for Cancer Product
Table 84. Merck & Co Recent Developments/Updates
Table 85. Clovis Oncology Corporation Information
Table 86. Clovis Oncology Description and Business Overview
Table 87. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Clovis Oncology PARP Inhibitors for Cancer Product
Table 89. Clovis Oncology Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Pfizer PARP Inhibitors for Cancer Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. PARP Inhibitors for Cancer Distributors List
Table 98. PARP Inhibitors for Cancer Customers List
Table 99. PARP Inhibitors for Cancer Market Trends
Table 100. PARP Inhibitors for Cancer Market Drivers
Table 101. PARP Inhibitors for Cancer Market Challenges
Table 102. PARP Inhibitors for Cancer Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of PARP Inhibitors for Cancer
Figure 2. Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global PARP Inhibitors for Cancer Market Share by Type in 2022 & 2029
Figure 4. Lynparza Product Picture
Figure 5. Zejula Product Picture
Figure 6. Rubraca Product Picture
Figure 7. Talzenna Product Picture
Figure 8. Other Product Picture
Figure 9. Global PARP Inhibitors for Cancer Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global PARP Inhibitors for Cancer Market Share by Application in 2022 & 2029
Figure 11. Ovarian Cancer
Figure 12. Breast Cancer
Figure 13. Other
Figure 14. Global PARP Inhibitors for Cancer Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global PARP Inhibitors for Cancer Market Size (2018-2029) & (US$ Million)
Figure 16. Global PARP Inhibitors for Cancer Sales (2018-2029) & (K Units)
Figure 17. Global PARP Inhibitors for Cancer Average Price (US$/Unit) & (2018-2029)
Figure 18. PARP Inhibitors for Cancer Report Years Considered
Figure 19. PARP Inhibitors for Cancer Sales Share by Manufacturers in 2022
Figure 20. Global PARP Inhibitors for Cancer Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest PARP Inhibitors for Cancer Players: Market Share by Revenue in 2022
Figure 22. PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global PARP Inhibitors for Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 25. North America PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 26. United States PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 29. Europe PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 30. Germany PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific PARP Inhibitors for Cancer Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2029)
Figure 37. China PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Indonesia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Thailand PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Malaysia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 47. Latin America PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 48. Mexico PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 53. Turkey PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. UAE PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of PARP Inhibitors for Cancer by Type (2018-2029)
Figure 57. Global Revenue Market Share of PARP Inhibitors for Cancer by Type (2018-2029)
Figure 58. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of PARP Inhibitors for Cancer by Application (2018-2029)
Figure 60. Global Revenue Market Share of PARP Inhibitors for Cancer by Application (2018-2029)
Figure 61. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2018-2029)
Figure 62. PARP Inhibitors for Cancer Value Chain
Figure 63. PARP Inhibitors for Cancer Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Figure 1. Product Picture of PARP Inhibitors for Cancer
Figure 2. Global PARP Inhibitors for Cancer Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global PARP Inhibitors for Cancer Market Share by Type in 2022 & 2029
Figure 4. Lynparza Product Picture
Figure 5. Zejula Product Picture
Figure 6. Rubraca Product Picture
Figure 7. Talzenna Product Picture
Figure 8. Other Product Picture
Figure 9. Global PARP Inhibitors for Cancer Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global PARP Inhibitors for Cancer Market Share by Application in 2022 & 2029
Figure 11. Ovarian Cancer
Figure 12. Breast Cancer
Figure 13. Other
Figure 14. Global PARP Inhibitors for Cancer Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global PARP Inhibitors for Cancer Market Size (2018-2029) & (US$ Million)
Figure 16. Global PARP Inhibitors for Cancer Sales (2018-2029) & (K Units)
Figure 17. Global PARP Inhibitors for Cancer Average Price (US$/Unit) & (2018-2029)
Figure 18. PARP Inhibitors for Cancer Report Years Considered
Figure 19. PARP Inhibitors for Cancer Sales Share by Manufacturers in 2022
Figure 20. Global PARP Inhibitors for Cancer Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest PARP Inhibitors for Cancer Players: Market Share by Revenue in 2022
Figure 22. PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global PARP Inhibitors for Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 25. North America PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 26. United States PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 29. Europe PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 30. Germany PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific PARP Inhibitors for Cancer Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2029)
Figure 37. China PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Indonesia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Thailand PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Malaysia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 47. Latin America PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 48. Mexico PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa PARP Inhibitors for Cancer Revenue Market Share by Country (2018-2029)
Figure 53. Turkey PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. UAE PARP Inhibitors for Cancer Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of PARP Inhibitors for Cancer by Type (2018-2029)
Figure 57. Global Revenue Market Share of PARP Inhibitors for Cancer by Type (2018-2029)
Figure 58. Global PARP Inhibitors for Cancer Price (US$/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of PARP Inhibitors for Cancer by Application (2018-2029)
Figure 60. Global Revenue Market Share of PARP Inhibitors for Cancer by Application (2018-2029)
Figure 61. Global PARP Inhibitors for Cancer Price (US$/Unit) by Application (2018-2029)
Figure 62. PARP Inhibitors for Cancer Value Chain
Figure 63. PARP Inhibitors for Cancer Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
